Accepted for Publication: June 9, 2011.
Author Contributions: Drs Mullins and Kahn had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Zimet, Rosenthal, Fortenberry, Bernstein, and Kahn. Acquisition of data: Morrow and Kahn. Analysis and interpretation of data: Mullins, Zimet, Ding, Shew, and Kahn. Drafting of the manuscript: Mullins. Critical revision of the manuscript for important intellectual content: Zimet, Rosenthal, Morrow, Ding, Shew, Fortenberry, Bernstein, and Kahn. Statistical analysis: Ding. Obtained funding: Shew and Kahn. Administrative, technical, and material support: Mullins, Morrow, Fortenberry, and Bernstein. Study supervision: Zimet and Kahn.
Financial Disclosure: Drs Zimet and Rosenthal have received investigator-initiated grants from Merck. Dr Zimet has consulted with Sanofi Pasteur regarding attitudes about herpes simplex virus 2 vaccination. Dr Rosenthal has served on a Merck advisory board. Dr Shew is an investigator for an HPV vaccine clinical trial and serves on the speakers’ bureau for Merck. Dr Kahn is a co–primary investigator for a National Institutes of Health–funded clinical trial of HPV vaccine in HIV-infected individuals in which immunogenicity testing and HPV vaccines are provided by Merck.
Funding/Support: This study was supported through National Institutes of Health (National Institute of Allergy and Infectious Diseases) grant R01 073713 (primary investigator: Jessica A. Kahn, MD, MPH) and National Research Service Award training grant HRSA T32HP10027 (Dr Mullins; primary investigator: Robert Kahn, MD, MPH).
Additional Contributions: Lisa Higgins, RPh, performed data management for the study.